Table 1 Demographics of patients included in the analysis
From: Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Patient characteristics | Drug | Placebo | P value |
|---|---|---|---|
(n = 4) | (n = 5) | ||
Age (years) | 54.5 ± 17.3 | 58.8 ± 9.5 | 0.64 |
Sex (F, n) | 1 | 1 | 0.99 |
BMI | 30.15 ± 5.1 | 28.8 ± 5.9 | 0.72 |
FEV1 %predicted | 60 ± 15.5 | 51.6 ± 13.1 | 0.41 |
FEV1/VC | 0.64 ± 0.15 | 0.56 ± 0.09 | 0.36 |
Serum IgE | 965 ± 1499 | 482 ± 696 | 0.58 |
ACQ-5 | 1.79 ± 0.5 | 2.2 ± 0.67 | 0.35 |
Blood eosinophil (× 109/L) | 0.35 ± 0.23 | 0.62 ± 0.50 | 0.36 |
Sputum eosinophil (%) | 15.75 ± 11.1 | 22.18 ± 14.02 | 0.5 |
Prednisone use (n) | 1 (4) | 0 | 0.29 |
Inhaled corticosteroid (median, max–min) | 1450 (2000, 800) | 1500 (2400, 1250) | 0.37 |